Developer docs
API playgroundTry for free, no card

Search company profiles

Theragen Bio

Full company profile

uuid0009kfy

Namestring
Theragen Bio
Legal namestring
(주)테라젠바이오
Websiteurl
theragenbio.com
Company typeenum
Private
Founded yearint
2010
Descriptiontext

Theragen Bio is a South Korea-based genomic services and AI-driven biopharmaceutical company providing next-generation sequencing (NGS)-based genomic analysis, bioinformatics services, and personalized cancer therapeutics development. The company operates as a subsidiary of Theragen Etex with 51-100 employees, headquartered in Suwon, Gyeonggi-do, and serves healthcare and medical institutions, pharmaceutical and biotech companies, academic researchers, and consumer health segments. In 2025, the company reported revenue of 10.5 billion KRW (~$7.5M USD) and achieved its first net profit of 920 million KRW with a 23.8% improvement in operating loss. The company holds ISO 27001 and ISO 27701 certifications maintained for four consecutive years and is currently expanding internationally, with sales beginning in Japan in Q1 2025.

The company's core technology is the proprietary DEEPOMICS AI platform, comprising three deep learning modules: DEEPOMICS NEO (personalized neoantigen prediction incorporating both MHC-peptide binding and T-cell activation), DEEPOMICS MARKER (automated disease subtype classification from transcriptome data), and DEEPOMICS FFPE (deep neural network-based removal of artifacts from formalin-fixed paraffin-embedded tissue samples). DEEPOMICS NEO is protected by three registered patents covering HLA Class I prediction, HLA Class II prediction, and rare HLA resolution specifically tuned for East Asian populations, while the FFPE methodology was peer-reviewed and published in Scientific Reports in February 2024. Supporting infrastructure includes a high-throughput Illumina NovaSeq 6000 S4 platform (1,000th run milestone achieved December 2023) and the first Element Biosciences AVITI system installed in South Korea. The company has strategic integrations with Agilent (NGS pipeline co-development, 2023), Arontier (joint AI cancer vaccine platform development, 2024), Korea University Ansan Hospital (clinical research MOU, 2023), and participates in Korea's PAVE (ARPA-H equivalent) personalized cancer vaccine initiative.

Theragen Bio monetizes through multiple revenue streams: NGS sequencing services (including proprietary TCR Seq), bioinformatics and clinical sequencing analysis, Bio IT solutions (NGS LIMS, Healthcare LIMS, Genome Browser), and direct-to-consumer healthcare offerings (TherAbiome microbiome analysis, Hellojin disease prediction, Genestyle DTC genetic testing) distributed through the Theragen Health subsidiary and partner channels including Genestyle Mall. A drug discovery platform developing personalized cancer vaccines using NGS, mRNA, and LNP technologies is in development, with the first-in-class "dark matter" therapeutic R&D effort backed by partnerships with Arontier and participation in the Korean PAVE project. The company has also been selected as priority negotiating partner for genome production institution in the National Integrated Bio Big Data Construction Project (October 2024), positioning it as a foundational player in Korea's national genomic data infrastructure.

Short descriptiontext

Theragen Bio is a South Korean genomic services and AI-driven biopharmaceutical company providing NGS sequencing, bioinformatics analysis, Bio IT solutions, and personalized cancer vaccine development through its proprietary DEEPOMICS platform, serving pharmaceutical, healthcare, and research organizations in Korea and Japan.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSeongnam, South Korea
HQ citystring
Seongnam
HQ countrystring
South Korea
HQ regionstring
Asia
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
genomic sequencing services, bioinformatics analysis, clinical NGS sequencing, AI neoantigen prediction, microbiome analysis services
Industry4 codes
PRIMARYHLAGAJAD
Bioinformatics & Multi-omics Analysis Software
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGANAI
Bioinformatics, Multi-Omics Data Analysis & Interpretation Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAGANAE
Transcriptomics & Gene Expression Profiling Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAAALAO
Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays)
NAICS code2 codes
  • Medical and Diagnostic Laboratories6215
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code3 codes
  • Services-Medical Laboratories8071
  • In Vitro & In Vivo Diagnostic Substances2835
  • Services-Health Services8000
Product category
Genomics & Bioinformatics Services
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model6 records
1NGS Services
TypeSubscription Recurring
Description

Next Generation Sequencing services including TCR Seq (T-cell receptor sequencing) services that have been localized using proprietary technology

venturesquare.net
2Bioinformatics Services
TypeSubscription Recurring
Description

Bioinformatics analysis services using proprietary DEEPOMICS platform

theragenbio.com
3Clinical Sequencing
TypeSubscription Recurring
Description

Clinical sequencing services for diagnostic purposes

theragenbio.com
4Bio IT Solutions
TypeSubscription Recurring
Description

LIMS solutions for NGS and healthcare including NGS LIMS and Healthcare LIMS

theragenbio.com
5Healthcare Services
TypeSubscription Recurring
Description

Direct-to-consumer and clinical microbiome analysis services (TherAbiome, Hellojin, GenStyle)

theragenbio.com
6Drug Discovery Platform
TypeLicensing Royalties
Description

First-in-class dark matter therapeutic R&D including personalized cancer vaccines using NGS, mRNA, and LNP technologies

theragenbio.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales, Supply Chain
GTM typeB2B and B2C
B2B and B2C
Offering typeServices
Services
Brand1 of 7 records shown
1TherAbiome (테라바이옴)
Description

Microbiome analysis service that analyzes gut microbiome using Next Generation Sequencing technology to provide personalized health monitoring including gut health, metabolism, cardiovascular health, and lifestyle tips.

theragenbio.com
+6 more records
Core offering1 text field

Theragen Bio is a global genomic service provider and AI-based biopharmaceutical company offering NGS sequencing services, bioinformatics analysis, clinical sequencing, and Bio IT solutions (NGS LIMS, Healthcare LIMS, Genome Browser) to enterprise clients in healthcare and pharma. Its core differentiator is the proprietary DEEPOMICS® AI platform with modules for neoantigen prediction, disease subtyping, and FFPE artifact removal, underpinning personalized cancer vaccine R&D and precision medicine workflows. Direct-to-consumer microbiome analysis (TherAbiome) and genetic risk prediction (Hellojin, Genestyle) services are offered alongside, primarily through its Theragen Health subsidiary.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • DEEPOMICS® NEO demonstrated superior anti-tumor efficacy in B16F10 melanoma tumor model compared to conventional methods in preclinical studies
+1 more record
Product overview1 text field

Theragen Bio is a global genome analysis service and platform-based new drug development company offering an integrated portfolio of NGS-based genomic services and AI-powered bioinformatics solutions. The core offering centers on the DEEPOMICS AI platform with three modules: DEEPOMICS NEO (AI-based neoantigen prediction for personalized cancer vaccines), DEEPOMICS MARKER (disease subtype classification and biomarker discovery), and DEEPOMICS FFPE (deep learning-based variant calling for FFPE samples). Supporting services include NGS sequencing, bioinformatics analysis, clinical sequencing, and Bio IT solutions (NGS LIMS, Healthcare LIMS, Genome Browser). Healthcare offerings comprise THERAbiome (microbiome analysis), 헬로진 (cancer/disease prediction), and 진스타일 (DTC healthcare). The company serves pharmaceutical companies, healthcare institutions, and research organizations with genomic data services and precision medicine solutions.

Product and service13 records
1NGS Services
CategoryGenomic Sequencing Services
Description

Next-generation sequencing services providing comprehensive genomic profiling, data generation, and analysis for healthcare institutions, pharmaceutical companies, and research organizations.

2Bioinformatics Services
CategoryBioinformatics Analysis Services
Description

Bioinformatics data analysis services leveraging proprietary DEEPOMICS® AI platform and deep learning capabilities to interpret complex genomic data for research and clinical applications.

3Clinical Sequencing
CategoryClinical Genomic Services
Description

Clinical-grade sequencing services for diagnostic and precision medicine applications, providing clinical decision support for healthcare providers.

4NGS LIMS
CategoryLaboratory Software / Bio IT
Description

Laboratory Information Management System (LIMS) designed for NGS workflows and genomic data management, providing sample tracking, workflow management, and data integrity controls for genomics laboratories.

5Healthcare LIMS
CategoryLaboratory Software / Bio IT
Description

Healthcare-focused laboratory information management system for clinical and diagnostic operations, supporting sample management, reporting, and compliance for healthcare institutions.

6Genome Browser
CategoryLaboratory Software / Bio IT
Description

Genomic data visualization and browsing tool for analyzing and interpreting genomic information, supporting researchers and clinicians in exploring sequencing results.

7TherAbiome (테라바이옴)
CategoryConsumer Health / Microbiome Testing
Description

Microbiome analysis service using NGS technology to analyze gut microorganisms and provide personalized health monitoring and therapy recommendations, including gut health, metabolism, cardiovascular health, and lifestyle insights.

8Hellojin (헬로진)
CategoryConsumer Health / Genetic Risk Prediction
Description

Direct-to-consumer cancer and disease prediction service providing personalized health risk assessments through genomic analysis for early disease risk awareness.

9Genestyle (진스타일)
CategoryConsumer Health / Genetic Testing
Description

Direct-to-consumer (DTC) healthcare service offering personal genetic testing and health risk assessment services, distributed through the Theragen Health subsidiary and Genestyle Mall partner channel.

10DEEPOMICS NEO
CategoryAI Platform / Drug Discovery
Description

AI-based personalized neoantigen prediction platform that identifies somatic mutations in patient tumor tissue and predicts patient-specific neoantigens tailored to individual MHC profiles using deep learning models that consider both MHC-neoantigen binding and T-cell activation. Offered as a co-development platform for cancer vaccine R&D with pharmaceutical partners.

11DEEPOMICS MARKER
CategoryAI Platform / Biomarker Discovery
Description

Deep learning-based platform that automatically discovers and classifies disease molecular subtypes and identifies specific biomarkers and signatures for each subtype from transcriptome data without requiring normal controls. Supports patient stratification and therapeutic target identification for pharmaceutical research.

12DEEPOMICS FFPE
CategoryAI Platform / Bioinformatics
Description

Deep neural network-based AI model that removes FFPE-derived artifacts while preserving true somatic mutations, enabling accurate variant calling from challenging formalin-fixed paraffin-embedded tissue samples commonly used in cancer research and clinical archives.

13T-cell Receptor Sequencing (TCR Seq)
CategoryGenomic Sequencing Services
Description

Proprietary T-cell receptor sequencing service using localized proprietary technology capable of analyzing difficult FFPE samples with high efficiency for immuno-oncology research and cancer vaccine development.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
1Korean National Integrated Bio Big Data Construction Project
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-10-29
Description

Selected as priority negotiating partner (유전체 생산기관 우선협상대상자) for the National Integrated Bio Big Data Construction Project genome production institution, indicating government-level partnership for national genomic data infrastructure.

theragenbio.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-01-17
Description

Joint development contract for AI-based personalized cancer vaccine design platform using DEEPOMICS® NEO technology. Collaboration aimed at developing personalized cancer vaccine design capabilities.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2023-12-08
Description

Achieved Illumina NovaSeq 6000 S4 1000th run milestone, demonstrating high-volume sequencing capabilities and strong partnership with Illumina for next-generation sequencing services.

4Korea Bio Master High School (한국바이오마스터고)
Strategic tierMinorTypeOthersAnnounced on2023-12-07
Description

Donated genetic analysis equipment to Korea Bio Master High School for educational purposes, demonstrating corporate social responsibility.

theragenbio.com
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2023-09-25
Description

NGS analysis pipeline development MOU for genomic profiling collaboration with Agilent (NASDAQ: A), enhancing genomic profiling capabilities through joint development of NGS analysis pipelines.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-07-10
Description

MOU for precise genome information production and analysis collaboration with Korea University Ansan Hospital, strengthening clinical research capabilities.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Participation in the Korean ARPA-H project (PAVE) for developing personalized cancer vaccines using NGS, mRNA, and LNP technologies. International collaborative research initiative for next-generation therapeutic development.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Foundation Medicine is a leading molecular profiling company offering comprehensive genomic profiling assays for oncology. Comparable as a clinical NGS + bioinformatics services peer, though much larger and wholly owned by Roche, giving it incumbent scale advantages Theragen Bio lacks.

TypeDirect peer
Description

Personalis is a US-based cancer genomics company combining NGS with proprietary AI for tumor molecular profiling and neoantigen discovery (ImmunoID Next platform). Comparable to Theragen Bio on the AI-driven oncology genomics and neoantigen prediction value proposition.

3Takara Bio
TypeRegional player
Description

Takara Bio is a Japanese life-sciences company offering reagents, NGS services, and cell/gene therapy tools across Asia. Comparable as a regional player offering NGS-adjacent services and instruments to pharma/academic customers in the same geographies where Theragen Bio is expanding.

4Tempus AI
TypeBroad incumbent
Description

Tempus AI is a large-scale AI-powered precision medicine company offering NGS, multimodal data, and bioinformatic analysis to oncologists and pharma. Comparable on the AI-bioinformatics platform thesis, though operating at much larger scale across a broader portfolio than Theragen Bio's focused offering.

TypeRegional player
Description

Novogene is a leading Asia-Pacific NGS services provider with strong footprint in China and global pharma clients. Comparable as a regional NGS services competitor, particularly relevant as Theragen Bio expands into Japan and broader East Asia.

TypeBroad incumbent
Description

BGI Group operates one of the world's largest genomic sequencing and bioinformatics service operations across clinical, agricultural, and research applications. Comparable on the genomics-services-plus-platform thesis, though operating as a global incumbent at materially larger scale.

TypeDirect peer
Description

Guardant Health provides liquid-biopsy NGS-based oncology testing and biopharma services, including AI-driven interpretation. Comparable as a clinical NGS services + AI-bioinformatics company targeting precision oncology — a core customer segment for Theragen Bio.

TypeDirect peer
Description

Caris offers molecular profiling plus ADAPT AI-based platform for biomarker discovery and therapy matching in oncology. Directly comparable to Theragen Bio's DEEPOMICS MARKER/Molecular-subtype-discovery approach combined with clinical sequencing services.

TypeDirect peer
Description

Macrogen is a Korean-headquartered genomic services and precision medicine company offering NGS, bioinformatics, and clinical sequencing to pharma and academic clients. It is the most direct domestic competitor to Theragen Bio, with a comparable services-plus-bioinformatics model and similar Korean academic/hospital customer base.

10DNA Link
TypeDirect peer
Description

DNA Link is a Korean NGS services and bioinformatics provider serving clinical, academic, and pharma customers with DNA sequencing and AI-based analysis. It overlaps Theragen Bio on services portfolio, target segments (hospitals and research institutions), and Korean-market positioning.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Theragen Bio

Genomics & Bioinformatics Servicestheragenbio.com

Theragen Bio is a South Korean genomic services and AI-driven biopharmaceutical company providing NGS sequencing, bioinformatics analysis, Bio IT solutions, and personalized cancer vaccine development through its proprietary DEEPOMICS platform, serving pharmaceutical, healthcare, and research organizations in Korea and Japan.

What Theragen Bio does

Theragen Bio is a South Korea-based genomic services and AI-driven biopharmaceutical company providing next-generation sequencing (NGS)-based genomic analysis, bioinformatics services, and personalized cancer therapeutics development. The company operates as a subsidiary of Theragen Etex with 51-100 employees, headquartered in Suwon, Gyeonggi-do, and serves healthcare and medical institutions, pharmaceutical and biotech companies, academic researchers, and consumer health segments. In 2025, the company reported revenue of 10.5 billion KRW (~$7.5M USD) and achieved its first net profit of 920 million KRW with a 23.8% improvement in operating loss. The company holds ISO 27001 and ISO 27701 certifications maintained for four consecutive years and is currently expanding internationally, with sales beginning in Japan in Q1 2025.

The company's core technology is the proprietary DEEPOMICS AI platform, comprising three deep learning modules: DEEPOMICS NEO (personalized neoantigen prediction incorporating both MHC-peptide binding and T-cell activation), DEEPOMICS MARKER (automated disease subtype classification from transcriptome data), and DEEPOMICS FFPE (deep neural network-based removal of artifacts from formalin-fixed paraffin-embedded tissue samples). DEEPOMICS NEO is protected by three registered patents covering HLA Class I prediction, HLA Class II prediction, and rare HLA resolution specifically tuned for East Asian populations, while the FFPE methodology was peer-reviewed and published in Scientific Reports in February 2024. Supporting infrastructure includes a high-throughput Illumina NovaSeq 6000 S4 platform (1,000th run milestone achieved December 2023) and the first Element Biosciences AVITI system installed in South Korea. The company has strategic integrations with Agilent (NGS pipeline co-development, 2023), Arontier (joint AI cancer vaccine platform development, 2024), Korea University Ansan Hospital (clinical research MOU, 2023), and participates in Korea's PAVE (ARPA-H equivalent) personalized cancer vaccine initiative.

Theragen Bio monetizes through multiple revenue streams: NGS sequencing services (including proprietary TCR Seq), bioinformatics and clinical sequencing analysis, Bio IT solutions (NGS LIMS, Healthcare LIMS, Genome Browser), and direct-to-consumer healthcare offerings (TherAbiome microbiome analysis, Hellojin disease prediction, Genestyle DTC genetic testing) distributed through the Theragen Health subsidiary and partner channels including Genestyle Mall. A drug discovery platform developing personalized cancer vaccines using NGS, mRNA, and LNP technologies is in development, with the first-in-class "dark matter" therapeutic R&D effort backed by partnerships with Arontier and participation in the Korean PAVE project. The company has also been selected as priority negotiating partner for genome production institution in the National Integrated Bio Big Data Construction Project (October 2024), positioning it as a foundational player in Korea's national genomic data infrastructure.

Theragen Bio firmographics

Firmographics
Name
Theragen Bio
Legal name
(주)테라젠바이오
Website
https://theragenbio.com
Company type
Private
Founded year
2010
Operating status
Operating
Headcount range
11–50 employees
Short description
Theragen Bio is a South Korean genomic services and AI-driven biopharmaceutical company providing NGS sequencing, bioinformatics analysis, Bio IT solutions, and personalized cancer vaccine development through its proprietary DEEPOMICS platform, serving pharmaceutical, healthcare, and research organizations in Korea and Japan.
Ownership category
akta.pro rank

Theragen Bio industry classification

Industry
Product category
Genomics & Bioinformatics Services
NAICS
Medical and Diagnostic Laboratories (6215), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835), Services-Health Services (8000)
akta.pro industry
PRIMARYHLAGAJAD
Bioinformatics & Multi-omics Analysis Software
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGANAI
Bioinformatics, Multi-Omics Data Analysis & Interpretation Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAGANAE
Transcriptomics & Gene Expression Profiling Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAAALAO
Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays)

Keywords

  • Genomic sequencing services
  • Bioinformatics analysis
  • Clinical NGS sequencing
  • AI neoantigen prediction
  • Microbiome analysis services

Where Theragen Bio is headquartered

Location

Headquarters

HQ city
Seongnam
HQ country
South Korea
HQ region
Asia

Offices1 record

Markets served

Theragen Bio business model

Business model
GTM type
B2B and B2C
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

  1. NGS Services: Next Generation Sequencing services including TCR Seq (T-cell receptor sequencing) services that have been localized using proprietary technology
  2. Bioinformatics Services: Bioinformatics analysis services using proprietary DEEPOMICS platform
  3. Clinical Sequencing: Clinical sequencing services for diagnostic purposes
  4. Bio IT Solutions: LIMS solutions for NGS and healthcare including NGS LIMS and Healthcare LIMS
  5. Healthcare Services: Direct-to-consumer and clinical microbiome analysis services (TherAbiome, Hellojin, GenStyle)
  6. Drug Discovery Platform: First-in-class dark matter therapeutic R&D including personalized cancer vaccines using NGS, mRNA, and LNP technologies

Go-to-market motion2 records

Distribution channels4 records

Marketing channels4 records

Theragen Bio product offering

Product offering

Core offering

Theragen Bio is a global genomic service provider and AI-based biopharmaceutical company offering NGS sequencing services, bioinformatics analysis, clinical sequencing, and Bio IT solutions (NGS LIMS, Healthcare LIMS, Genome Browser) to enterprise clients in healthcare and pharma. Its core differentiator is the proprietary DEEPOMICS® AI platform with modules for neoantigen prediction, disease subtyping, and FFPE artifact removal, underpinning personalized cancer vaccine R&D and precision medicine workflows. Direct-to-consumer microbiome analysis (TherAbiome) and genetic risk prediction (Hellojin, Genestyle) services are offered alongside, primarily through its Theragen Health subsidiary.

Product overview

Theragen Bio is a global genome analysis service and platform-based new drug development company offering an integrated portfolio of NGS-based genomic services and AI-powered bioinformatics solutions. The core offering centers on the DEEPOMICS AI platform with three modules: DEEPOMICS NEO (AI-based neoantigen prediction for personalized cancer vaccines), DEEPOMICS MARKER (disease subtype classification and biomarker discovery), and DEEPOMICS FFPE (deep learning-based variant calling for FFPE samples). Supporting services include NGS sequencing, bioinformatics analysis, clinical sequencing, and Bio IT solutions (NGS LIMS, Healthcare LIMS, Genome Browser). Healthcare offerings comprise THERAbiome (microbiome analysis), 헬로진 (cancer/disease prediction), and 진스타일 (DTC healthcare). The company serves pharmaceutical companies, healthcare institutions, and research organizations with genomic data services and precision medicine solutions.

Differentiator

Problem solved

Functional benefit

Brands

  • TherAbiome (테라바이옴): Microbiome analysis service that analyzes gut microbiome using Next Generation Sequencing technology to provide personalized health monitoring including gut health, metabolism, cardiovascular health, and lifestyle tips.
  • Genestyle (진스타일)
  • Hellojin (헬로진)
  • DEEPOMICS®
  • DEEPOMICS® NEO
  • DEEPOMICS® MARKER
  • DEEPOMICS® FFPE

Products and services

  • NGS Services Next-generation sequencing services providing comprehensive genomic profiling, data generation, and analysis for healthcare institutions, pharmaceutical companies, and research organizations.
  • Bioinformatics Services Bioinformatics data analysis services leveraging proprietary DEEPOMICS® AI platform and deep learning capabilities to interpret complex genomic data for research and clinical applications.
  • Clinical Sequencing Clinical-grade sequencing services for diagnostic and precision medicine applications, providing clinical decision support for healthcare providers.
  • NGS LIMS Laboratory Information Management System (LIMS) designed for NGS workflows and genomic data management, providing sample tracking, workflow management, and data integrity controls for genomics laboratories.
  • Healthcare LIMS Healthcare-focused laboratory information management system for clinical and diagnostic operations, supporting sample management, reporting, and compliance for healthcare institutions.
  • Genome Browser Genomic data visualization and browsing tool for analyzing and interpreting genomic information, supporting researchers and clinicians in exploring sequencing results.
  • TherAbiome (테라바이옴) Microbiome analysis service using NGS technology to analyze gut microorganisms and provide personalized health monitoring and therapy recommendations, including gut health, metabolism, cardiovascular health, and lifestyle insights.
  • Hellojin (헬로진) Direct-to-consumer cancer and disease prediction service providing personalized health risk assessments through genomic analysis for early disease risk awareness.
  • Genestyle (진스타일) Direct-to-consumer (DTC) healthcare service offering personal genetic testing and health risk assessment services, distributed through the Theragen Health subsidiary and Genestyle Mall partner channel.
  • DEEPOMICS NEO AI-based personalized neoantigen prediction platform that identifies somatic mutations in patient tumor tissue and predicts patient-specific neoantigens tailored to individual MHC profiles using deep learning models that consider both MHC-neoantigen binding and T-cell activation. Offered as a co-development platform for cancer vaccine R&D with pharmaceutical partners.
  • DEEPOMICS MARKER Deep learning-based platform that automatically discovers and classifies disease molecular subtypes and identifies specific biomarkers and signatures for each subtype from transcriptome data without requiring normal controls. Supports patient stratification and therapeutic target identification for pharmaceutical research.
  • DEEPOMICS FFPE Deep neural network-based AI model that removes FFPE-derived artifacts while preserving true somatic mutations, enabling accurate variant calling from challenging formalin-fixed paraffin-embedded tissue samples commonly used in cancer research and clinical archives.
  • T-cell Receptor Sequencing (TCR Seq) Proprietary T-cell receptor sequencing service using localized proprietary technology capable of analyzing difficult FFPE samples with high efficiency for immuno-oncology research and cancer vaccine development.

Quantifiable outcome

  • DEEPOMICS® NEO demonstrated superior anti-tumor efficacy in B16F10 melanoma tumor model compared to conventional methods in preclinical studies
  • +1 more outcomes

Companies that use Theragen Bio

Customer profile

Segments4 records

Ideal customer profiles4 records

Theragen Bio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature3 records

Theragen Bio partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered core and minor.

  • Korean National Integrated Bio Big Data Construction ProjectcoreStrategic or Co-development Partner · 29 October 2024Selected as priority negotiating partner (유전체 생산기관 우선협상대상자) for the National Integrated Bio Big Data Construction Project genome production institution, indicating government-level partnership for national genomic data infrastructure.
  • ArontiercoreStrategic or Co-development Partner · 17 January 2024Joint development contract for AI-based personalized cancer vaccine design platform using DEEPOMICS® NEO technology. Collaboration aimed at developing personalized cancer vaccine design capabilities.
  • IlluminacoreTechnology or Integration · 8 December 2023Achieved Illumina NovaSeq 6000 S4 1000th run milestone, demonstrating high-volume sequencing capabilities and strong partnership with Illumina for next-generation sequencing services.
  • Korea Bio Master High School (한국바이오마스터고)minorOthers · 7 December 2023Donated genetic analysis equipment to Korea Bio Master High School for educational purposes, demonstrating corporate social responsibility.
  • AgilentcoreTechnology or Integration · 25 September 2023NGS analysis pipeline development MOU for genomic profiling collaboration with Agilent (NASDAQ: A), enhancing genomic profiling capabilities through joint development of NGS analysis pipelines.
  • Korea University Ansan Hospital (고대안산병원)coreStrategic or Co-development Partner · 10 July 2023MOU for precise genome information production and analysis collaboration with Korea University Ansan Hospital, strengthening clinical research capabilities.
  • PAVE (Korean ARPA-H)coreStrategic or Co-development PartnerParticipation in the Korean ARPA-H project (PAVE) for developing personalized cancer vaccines using NGS, mRNA, and LNP technologies. International collaborative research initiative for next-generation therapeutic development.

Scale indicators4 records

Recent moves7 records

Expansion highlights6 records

Theragen Bio competitors and assessment

Company assessment

Broad incumbents

  • Foundation Medicine: Foundation Medicine is a leading molecular profiling company offering comprehensive genomic profiling assays for oncology. Comparable as a clinical NGS + bioinformatics services peer, though much larger and wholly owned by Roche, giving it incumbent scale advantages Theragen Bio lacks.
  • Tempus AI: Tempus AI is a large-scale AI-powered precision medicine company offering NGS, multimodal data, and bioinformatic analysis to oncologists and pharma. Comparable on the AI-bioinformatics platform thesis, though operating at much larger scale across a broader portfolio than Theragen Bio's focused offering.
  • BGI Group: BGI Group operates one of the world's largest genomic sequencing and bioinformatics service operations across clinical, agricultural, and research applications. Comparable on the genomics-services-plus-platform thesis, though operating as a global incumbent at materially larger scale.

Direct peers

  • Personalis: Personalis is a US-based cancer genomics company combining NGS with proprietary AI for tumor molecular profiling and neoantigen discovery (ImmunoID Next platform). Comparable to Theragen Bio on the AI-driven oncology genomics and neoantigen prediction value proposition.
  • Guardant Health: Guardant Health provides liquid-biopsy NGS-based oncology testing and biopharma services, including AI-driven interpretation. Comparable as a clinical NGS services + AI-bioinformatics company targeting precision oncology — a core customer segment for Theragen Bio.
  • Caris Life Sciences: Caris offers molecular profiling plus ADAPT AI-based platform for biomarker discovery and therapy matching in oncology. Directly comparable to Theragen Bio's DEEPOMICS MARKER/Molecular-subtype-discovery approach combined with clinical sequencing services.
  • Macrogen: Macrogen is a Korean-headquartered genomic services and precision medicine company offering NGS, bioinformatics, and clinical sequencing to pharma and academic clients. It is the most direct domestic competitor to Theragen Bio, with a comparable services-plus-bioinformatics model and similar Korean academic/hospital customer base.
  • DNA Link: DNA Link is a Korean NGS services and bioinformatics provider serving clinical, academic, and pharma customers with DNA sequencing and AI-based analysis. It overlaps Theragen Bio on services portfolio, target segments (hospitals and research institutions), and Korean-market positioning.

Regional players

  • Takara Bio: Takara Bio is a Japanese life-sciences company offering reagents, NGS services, and cell/gene therapy tools across Asia. Comparable as a regional player offering NGS-adjacent services and instruments to pharma/academic customers in the same geographies where Theragen Bio is expanding.
  • Novogene: Novogene is a leading Asia-Pacific NGS services provider with strong footprint in China and global pharma clients. Comparable as a regional NGS services competitor, particularly relevant as Theragen Bio expands into Japan and broader East Asia.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Theragen Bio social profiles

Digital presence

Theragen Bio compliance and trust

Trust signal

Compliance2 records

Theragen Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Theragen Bio leadership team

Management profile

Number of profiles

Profiles3 records

Theragen Bio subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Theragen Bio funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Theragen Bio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Theragen Bio

What does Theragen Bio do?

Theragen Bio is a global genomic service provider and AI-based biopharmaceutical company offering NGS sequencing services, bioinformatics analysis, clinical sequencing, and Bio IT solutions (NGS LIMS, Healthcare LIMS, Genome Browser) to enterprise clients in healthcare and pharma. Its core differentiator is the proprietary DEEPOMICS® AI platform with modules for neoantigen prediction, disease subtyping, and FFPE artifact removal, underpinning personalized cancer vaccine R&D and precision medicine workflows. Direct-to-consumer microbiome analysis (TherAbiome) and genetic risk prediction (Hellojin, Genestyle) services are offered alongside, primarily through its Theragen Health subsidiary.

Is Theragen Bio a public or private company?

Theragen Bio is a private company. It is classified as corporate owned and is currently operating.

When was Theragen Bio founded?

Theragen Bio was founded in 2010. It employs 11 to 50 people.

Where is Theragen Bio based?

Theragen Bio is headquartered in Seongnam, South Korea, in the Asia region.

How does Theragen Bio make money?

Six revenue lines are on record. NGS Services are the primary driver. The others are bioinformatics Services, clinical Sequencing, bio IT Solutions, healthcare Services and drug Discovery Platform.

Who are Theragen Bio's main competitors?

Broad incumbents on record are Foundation Medicine, Tempus AI and BGI Group. Direct peers are Personalis, Guardant Health, Caris Life Sciences, Macrogen and DNA Link. Regional players are Takara Bio and Novogene.

Does Theragen Bio have an API?

No public API is recorded for Theragen Bio.

What industry is Theragen Bio in?

Theragen Bio's product category is Genomics & Bioinformatics Services. Its primary akta.pro industry code is HLAGAJAD, Bioinformatics & Multi-omics Analysis Software, with a secondary code of HLAGANAI, Bioinformatics, Multi-Omics Data Analysis & Interpretation Services. Its NAICS code is 6215 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
VenturesquareTeragen Bio aims to achieve a profit turnaround in 2025... expanding research projects domestically and internationally.Theragen Bio, a subsidiary of Theragen Etex, announced on the 25th that it achieved a profit turnaround in 2025, with revenue reaching 10.5 billion won, a 23.8% improvement in operating loss, and net profit of 920 million won. The company localized its T-cell receptor sequencing (TCR Seq) services using proprietary technology and resolved artificial mutations through its DEEPOMICS FFPE algorithm, while also securing multiple national research projects including the National Integrated Bio Big Data Construction Project. Looking ahead, Theragen Bio is participating in the Korean ARPA-H project (PAVE) to develop personalized cancer vaccines using NGS, mRNA, and LNP technologies, with Japan sales beginning to materialize in Q1 as part of its overseas expansion strategy.Hypersense-SoftwareHarnessing HPC and Cloud Pipelines to Tame the Genomic Data DelugeGenomic data has grown to petabyte scales and is projected to reach exabyte capacity within five years, prompting genetic testing laboratories to invest in high-performance computing (HPC) clusters and cloud platforms to manage sequencing output efficiently. Advanced bioinformatics pipelines enable labs to process genomic data through automated, multi-stage workflows that reduce processing times significantly, as demonstrated when Theragen Bio reduced analysis time from 40 hours to 4 hours using AWS cloud infrastructure. HyperSense Software positions itself as a technology partner helping labs implement cloud-based genomic pipelines, automate workflows, and achieve cost efficiencies through custom bioinformatics solutions.PR NewswireGene Panel Market to Expand by USD 5.4 Billion from 2024-2028, Driven by Increased Use in Cancer Therapie, AI's Impact on Market Trends- Technavio ReportTechnavio's market research report projects the global gene panel market to grow by USD 5.40 billion from 2024 to 2028, expanding at a compound annual growth rate of approximately 23.44%. The primary growth driver is the increasing adoption of gene panels in cancer-targeted therapies, with market players forming strategic collaborations such as Agilent Technologies signing an MOU with South Korea-based Theragen Bio to advance cancer genomic profiling capabilities. Key challenges include difficulties in implementing large Next-Generation Sequencing gene panels due to lack of knowledge about rare variants and inadequate bioinformatics infrastructure at smaller healthcare facilities.PR NewswireGene Panel Market size to record USD 3.23 billion growth from 2023-2027, Collaboration to maximize research efficiency is one of the key market trends, TechnavioThe global gene panel market is projected to grow by USD 3.23 billion from 2023 to 2027 at a Compound Annual Growth Rate of 18.21%, driven by strategic alliances between vendors and academic institutes to reduce costs and maximize research efficiency. A key example is the April 2023 partnership between Agilent Technologies and Theragen Bio in South Korea, which leverages their respective strengths in software development and cancer genomic profiling design to enhance localized analysis and treatment decision speed. The market faces implementation challenges due to limited knowledge of rare variants, insufficient functional studies, and inadequate bioinformatics infrastructure at many hospitals.24-7 Press Release[Pangyo Bio] Theragen Bio Patented AI-based Cancer Vaccine Design ProgramTheragen Bio completed patent registration for its AI-based cancer vaccine design program, DEEPOMICS NEO, which predicts immunogenicity of synthetic long peptides. The company says the vaccine showed superior immune response and treatment effects in preclinical models compared to competitors. It plans to continue R&D on personalized neoantigen vaccines.The Korea HeraldTheragen Bio, Macrogen, DNA Link picked for K-DNA pilot bizTheragen Bio, Macrogen, and DNA Link were selected for a Korean government bio big data pilot project to gather genomic data from 20,000 Koreans over two years. The consortium will analyze 7,500 DNA samples in the first year using next-generation sequencing. The project aims to build independent Korean genomic data for disease research.